Happy with previous assignments delivered by Aagami, its Netherlands HQ'd client has given Aagami a broader and long term assignment, for partnering in Asia region.

The client has a game changing First-in-class phase-3-ready drug candidate for Post-Operative Fibrosis (POF) with incredible adhesion prevention results.

The asset has an untapped $2.5 billion market potential. The drug prevents adhesion formation & delivers clinically relevant outcomes, key to surgeon adoption, reimbursement & commands premium pricing. Client recently released clinical trial results show that it is the first drug to show a statistically significant PREVENTION of adhesions following surgery.

Aagami is excited with this new assignment and is looking forward to enabling partnerships for the client in Asia.